You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.
The company said test volume for its Cologuard colorectal cancer test rose 66 percent during the quarter to 292,000.
The firm's diagnostics and genomics group saw a 13 percent year-over-year revenue increase in the first quarter.
Excluding a loss of business to LabCorp, total revenue increased 22 percent year over year in the fourth quarter, Luminex said.
Qiagen's Q4 revenues of $403.2 million fell short of the consensus analyst estimate though its adjusted EPS of $.40 was in line with Wall Street expectations.
Organically, the diagnostics segment was up 14 percent. Overall, the company's revenues grew 18 percent year over year during the quarter.
Within diagnostics, the firm posted molecular diagnostics revenues of $164.3 million, up 11 percent from $148.6 million in fiscal Q1 2018.
Alere rapid diagnostics revenues were $548 million in the quarter, driven by infectious disease and cardiometabolic testing product sales.
The firm also reaffirmed its previous guidance of 10 percent growth for fiscal 2019.
A busy second day of the JP Morgan conference saw Thermo Fisher's Marc Casper discuss the firm's R&D focus and Exact Sciences' Kevin Conroy discuss plans for Cologuard sales growth.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.